| Q38126357 | Androgen therapy in women: for whom and when |
| Q37826818 | Androgenic hormones and aging--the link with female sexual function. |
| Q44429302 | Androgens and Women at the Menopause and Beyond |
| Q51478179 | Androgens and sexual dysfunction in naturally and surgically menopausal women. |
| Q35207779 | Androgens in women |
| Q36946008 | Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved |
| Q34661852 | Aromatase inhibitors and inactivators for breast cancer therapy |
| Q37818155 | Circulating androgens in women: exercise-induced changes |
| Q35068769 | Circulating dehydroepiandrosterone sulfate levels in women who underwent bilateral salpingo-oophorectomy during the menopausal transition |
| Q36536461 | Dehydroepiandrosterone sulfate levels reflect endogenous luteinizing hormone production and response to human chorionic gonadotropin challenge in older female macaque (Macaca fascicularis). |
| Q34635722 | Dehydroepiandrosterone: a springboard hormone for female sexuality |
| Q58800984 | Effect of ACTH and hCG on the Expression of Gonadotropin-Inducible Ovarian Transcription Factor 1 () Gene in the Rat Adrenal Gland |
| Q36889050 | Effect of ovarian aging on androgen biosynthesis in a cynomolgus macaque model |
| Q78454412 | Endocrine treatment and prevention of breast and gynaecological cancers |
| Q46925977 | Endogenous hormones, muscle strength, and risk of fall-related fractures in older women |
| Q64235089 | Exogenous Testosterone Does Not Influence 11-Oxygenated C19 Steroid Concentrations in Healthy Postmenopausal Women |
| Q43591076 | High serum dehydroepiandrosterone sulfate is associated with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome |
| Q34723839 | Human adrenal cells that express both 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2) and cytochrome b5 (CYB5A) contribute to adrenal androstenedione production |
| Q33648005 | Immunoexpression of aromatase cytochrome P450 and 17β-hydroxysteroid dehydrogenase in women's ovaries after menopause |
| Q36367082 | Impact of androgens on fertility - physiological, clinical and therapeutic aspects |
| Q37355746 | Insulin and hyperandrogenism in women with polycystic ovary syndrome |
| Q46157943 | Intracrine androgen biosynthesis, metabolism and action revisited |
| Q37337613 | Loss of ovarian function in the VCD mouse-model of menopause leads to insulin resistance and a rapid progression into the metabolic syndrome. |
| Q35197863 | Management of the androgen-deficient woman |
| Q37354259 | Multisteroid LC-MS/MS assay for glucocorticoids and androgens, and its application in Addison's disease |
| Q33820067 | Reproductive aging, sex steroids, and mood disorders |
| Q34181015 | Retaining Residual Ovarian Tissue following Ovarian Failure Has Limited Influence on Bone Loss in Aged Mice |
| Q34758613 | SHBG, sex hormones, and inflammatory markers in older women |
| Q33762391 | Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer |
| Q51805352 | Serum PSA levels are not affected by the menstrual cycle or the menopause, but are increased in subjects with polycystic ovary syndrome. |
| Q33938538 | Sex hormones and mood in the perimenopause |
| Q37262323 | Steroidogenic capacity of residual ovarian tissue in 4-vinylcyclohexene diepoxide-treated mice. |
| Q92642719 | Surgically Induced Menopause-A Practical Review of Literature |
| Q36026408 | The discovery and mechanism of action of letrozole |
| Q35151108 | The human postmenopausal ovary as a tool for evaluation of cryopreservation protocols towards whole ovary cryopreservation |
| Q78454437 | The origin of postmenopausal oestrogens |
| Q78390178 | The postmenopausal ovary as an androgen-producing gland; hypothesis on the etiology of endometrial cancer |
| Q34592879 | The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum |
| Q57989596 | The role of androgen therapy |
| Q38216899 | The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons |
| Q44349445 | Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin |
| Q34635758 | When to suspect androgen deficiency other than at menopause. |